A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective

Model scores of the 29,894 trials active now.

Model score 31% for any early termination, 20% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (851 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patientsmetastaticdlcreatininewomen
  Phrases that lowered it: evaluateefficacysubjectssafetysorafenib
• Sponsor's past termination rate: 21.2% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: parallel (raises risk) · Design
• Drug's FAERS reports marked serious: 69.6% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 10.2% (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 16801 (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Keywords listed: 16 (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 19 (lowers risk) · Sponsor's track record
• Blinding: none (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports before start: 81216 (lowers risk) · Drug's FDA history
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Sponsor's past trials: 33 (raises risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in Patients With Hepatocellular Carcinoma NCT02304289 · started 2014 · scored riskier than 50% of active trials terminated
• A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma NCT01192971 · started 2010 · scored riskier than 68% of active trials completed
• Evaluation of Intravenous Ascorbic Acid NCT01833351 · started 2011 · scored riskier than 24% of active trials completed
• Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA NCT01550510 · started 2011 · scored riskier than 96% of active trials terminated
• Vitamin C Intravenously With Chemotherapy in Advanced Colorectal Cancer NCT02969681 · started 2017 · scored riskier than 18% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.